Friday, July 05, 2024 8:52:18 AM
I studied a lot of published research in journals in my academic days. My wife publishes her research in journals. If a researcher says "we didn't meet our endpoint" or "there isn't enough data to draw a conclusion," the audience, including the CMS and your Joe Blow, is not going to analyze the data and cite that conclusion.
But I reiterate: there might be political pressure on the CMS to approve MORE devices and drugs, not LESS. So maybe it won't matter. Again, not the point of the discussion -- the point is that the company isn't doing anything else in preparation for the NOPAIN Act. You are the one trying to change the subject and move the goalpost.
Whatever. Slap That Ask if you think the CEO is doing such a great job. Show her your support.
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM